Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Amgen varlığının piyasadaki güncel fiyatı ₺17.944,11, 24 saatlik işlem hacmi ise ₺55,6M seviyesindedir. Varlığın piyasa değeri ₺9,68T olup son günde 0.66% değişim göstermiştir.
Tokenize edilmiş Amgen, ₺18.249,29 fiyattan işlem görüyor ve tokenize edilmiş piyasa değeri ₺156,42K, 24 saatlik işlem hacmi ise ₺40,51M. Tokenize edilmiş varlık son 24 saatte -3.85% hareket etti.